Work with LifeSpan to design a custom immunohistochemistry to address your specific biological question. Outsource the entire localization process without having to
worry about finding and characterizing target specific antibodies, sourcing and validating difficult-to-find tissues, and having the ability to interpret the resulting
immunostaining in relation to complex human pathologies.
TCR Screening Services
Test your therapeutic antibodies in immunohistochemistry against a broad panel of normal frozen human tissue types in order to determine potential unintended binding.
Our non-GLP TCR services are designed on the FDA recommendation outlined in their "Points to Consider in the Manufacture and Testing of Monoclonal Antibody Products for Human Use".
Description: Raclopride is a selective dopamine D2/D3 receptor antagonist with Ki values of 1.8, 3.5, 2,400, and 18,000 nM for D2, D3, D4, and D1 receptors, respectively. It passes the blood brain barrier and can be used in in vivo binding and autoradiography studies of the dopamine system under normal and pathological conditions such as Huntington's disease.
Raclopride is supplied as a solid. A stock solution may be made by dissolving the raclopride in the solvent of choice. Raclopride is soluble in organic solvents such as ethanol and DMSO, which should be purged with an inert gas. The solubility of raclopride in these solvents is approximately up to 20 and 100 mM, resepectively.
Seeman, P., and Van Tol, H.H.M. Dopamine receptor pharmacology. Trends. Pharmacol. Sci. 15(7), 264-270 (1994).
Lidow, M.S., Goldman-Rakic, P.S., Rakic, P., et al. Dopamine D2 receptors in the cerebral cortex: Distribution and pharmacological characterization with [3H]raclopride. Proc. Natl. Acad. Sci. USA 86, 6412-6416 (1989).
Ginovart, N. Imaging the dopamine system with in vivo [11C]raclopride displacement studies: Understanding the true mechanism. Mol. Imaging Biol. 7, 45-52 (2005).